Dragonfly Energy Holdings Corp. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Dragonfly Energy Holdings Corp. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.63M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $50.65M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $64.39M | Mar 31, 2025 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.63M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $50.65M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $64.39M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $86.25M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $78.00M | Apr 17, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.65M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $11.63M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $15.45M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $23.62M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $29.63M | Apr 17, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($69.94M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($40.62M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($13.82M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($39.99M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $4.34M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($1.0K) | Mar 29, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.17M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($25.76M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($27.43M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($34.38M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $6.47M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($1.0K) | Mar 29, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.98M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $5.45M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $3.86M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.76M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $2.69M | Apr 17, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($25.97M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($7.19M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($17.71M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($45.70M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($13.57M) | Apr 17, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.95M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $2.68M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $6.89M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $6.86M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $2.97M | Apr 17, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $86.55M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $75.21M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $75.20M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $89.11M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $76.25M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $25.0K | Mar 29, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.76M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $84.62M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $47.29M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $78.36M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $60.19M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $1.0K | Mar 29, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.53M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($9.40M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | $27.91M | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | $10.74M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $15.89M | Apr 16, 2024 |
| FY2022 | Dec 31, 2020 | $8.56M | Apr 17, 2023 |
| FY2021 | Jun 23, 2020 | $0 | Mar 29, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($152.09M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($82.15M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($41.54M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($27.72M) | Apr 16, 2024 |
| FY2023 | Jan 1, 2022 | $12.27M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $12.44M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($1.0K) | Mar 29, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.27M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $4.85M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $12.71M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $17.78M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $25.59M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $25.0K | Mar 29, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.34M | Mar 30, 2026 |
| FY2024 | Dec 31, 2024 | $85.91M | Mar 31, 2025 |
| FY2023 | Dec 31, 2023 | $75.86M | Apr 16, 2024 |
| FY2022 | Dec 31, 2022 | $76.19M | Apr 17, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (14) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (59) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 29, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (14) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (59) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 29, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 12.08M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 723,265 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 6.70M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 43.27M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 36.50M | Apr 17, 2023 |
| FY2021 | Aug 10, 2021 | 3.16M | Mar 29, 2022 |
| FY2021 | Mar 4, 2021 | 2.88M | Mar 29, 2022 |